| アブストラクト | PURPOSE: Our goal was to describe the management of pregestational diabetes in pregnant women in the United Kingdom. METHODS: We used electronic medical records from The Health Improvement Network database between January 1995 and June 2012 to identify the first pregnancy in women 15 to 45 years of age with pregestational diabetes type 1 or type 2. Information on lifestyle factors, demographic characteristics, prescription of specific antidiabetic medications, and glycemic control measures (HbA1c) was obtained from primary care provider records. We evaluated treatment patterns and HbA1c levels within 90 days before the last menstrual period (prepregnancy period) and within each trimester of pregnancy. RESULTS: In a cohort of 1511 pregnant women with pregestational diabetes, 60% had type 1 and 40% type 2 diabetes. Among women with type 1 diabetes, 90% received antidiabetic medication (primarily insulin) prepregnancy and 92% during the first trimester. Among women with type 2 diabetes, 54% received antidiabetic medication (primarily metformin) during the prepregnancy period and 60% during the first trimester. Among women with nontreated diabetes type 2 before pregnancy, 22% initiated treatment by the first trimester (primarily insulin); those on noninsulin antidiabetic medications often switched to insulin. The proportion of women with at least 1 HbA1c value recorded within the prepregnancy period was 33% for type 1 (n = 299) and 31% for type 2 diabetes (n = 189); the corresponding proportions within the first trimester were 48% and 40%, respectively. Among women with recorded HbA1c, the prevalence of HbA1c > 7% prepregnancy was 70% for type 1 and 52% for type 2 diabetes; the proportions within the first trimester were 73% and 46%, respectively. CONCLUSIONS: Management of pregnant women with diabetes seems to follow recommendations for pharmacological treatment. However, there is substantial room for improvement in HbA1c control, that is, in the planning of pregnancy in women with diabetes, in the initiation of antidiabetic medication among women with diabetes type 2 who may need it, and likely in the compliance with treatments in women with type 2 and type 1 diabetes. |
|---|
| ジャーナル名 | Pharmacoepidemiology and drug safety |
|---|
| Pubmed追加日 | 2018/5/10 |
|---|
| 投稿者 | Cea-Soriano, Lucia; Garcia-Rodriguez, Luis A; Brodovicz, Kimberly G; Masso-Gonzalez, Elvira; Bartels, Dorothee B; Hernandez-Diaz, Sonia |
|---|
| 組織名 | Department of Public Health and Maternal and Child Health, Faculty of Medicine,;Complutense University of Madrid, Madrid, Spain.;Spanish Centre for Pharmacoepidemiologic Research (CEIFE), Madrid, Spain.;Global Epidemiology, Boehringer Ingelheim Pharmacuticals, Inc, Ridgefield, CT,;USA.;Corp. Dept. Global Epidemiology, Boehringer Ingelheim GmbH, Ingelheim, Germany.;Hannover Medical School, Institute for Epidemiology, Social Medicine and Health;Systems Research, Hannover, Germany.;Department of Epidemiology, Harvard T.H. Chan School of Public Health, Boston,;MA, USA. |
|---|
| Pubmed リンク | https://www.ncbi.nlm.nih.gov/pubmed/29740916/ |
|---|
